A phase 2 study evaluated the efficacy and safety of adding pembrolizumab to trimodal therapy as a bladder-sparing approach for muscle-invasive bladder cancer (MIBC).

A global, multicenter phase III trial, TROPION-Breast02, led by a senior medical oncologist and researcher from the National ...

More than half of patients with recurrent/advanced disease were progression-free at 6 mont ...

Revised trial procedures add intensified hematologic and cardiac monitoring to mitigate toxicities consistent with dual ...

The company reported that its drug candidate, also known as zoci, achieved a 62.5% confirmed intracranial response rate at the 1.6 mg/kg dose level among 16 patients in an ongoing global Phase 1 trial ...

Also from SGO: p53 reactivator active in advanced gynecologic cancers, "perfect" score in ...

Potent preclinical efficacy with durable immune memory observed in combinations of either ACR-368 or ACR-2316 with anti-PD-L1 and strong synergy ...

Dr. Nooka provides comprehensive guidance on bispecific antibody safety management, emphasizing the predictable chronology of ...

Improvement in median overall survival of 2.9 months and decrease in risk for death reported with elraglusib/GnP vs GnP alone.

Zai Lab Limited today announced clinical data indicating zocilurtatug pelitecan (zoci, formerly ZL-1310), a DLL3-targeting antibody-drug conjugate (ADC), provides rapid and robust intracranial ...

A homegrown Northwestern drug is giving Chicago-area families something they almost never get with metastatic pancreatic ...

Learn expert-backed tips for lessening the negative effects of metastatic bladder cancer treatment.